CLGN

Collplant Biotechnologies Ltd
NASDAQHEALTHCAREBIOTECHNOLOGY

Key Statistics

Market Cap
$6.85M
P/E Ratio
—
EPS
$-9.33
Beta
0.76
52W High
$26.80
52W Low
$2.64
50-Day MA
$3.56
200-Day MA
$5.66
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
80.00
PEG Ratio
—

About Collplant Biotechnologies Ltd

CollPlant Biotechnologies Ltd., an aesthetic and regenerative medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. The company is headquartered in Rehovot, Israel.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)318,000
Gross Profit (TTM)$-1.02M
EBITDA$-11.56M
Operating Margin-2438.00%
Return on Equity-162.00%
Return on Assets-62.90%
Revenue/Share (TTM)$0.24
Book Value$2.04
Price-to-Book1.56
Price-to-Sales (TTM)21.55
EV/Revenue15.49
EV/EBITDA-5.97
Quarterly Earnings Growth (YoY)0.00%
Quarterly Revenue Growth (YoY)-39.70%
Shares Outstanding$1.89M
Float869,600
% Insiders33.56%
% Institutions9.93%

Historical Volatility

HV 10-Day
140.23%
HV 20-Day
115.52%
HV 30-Day
114.24%
HV 60-Day
113.01%
HV Rank
—

Volatility is currently expanding

Latest News

COLLPLANT ANNOUNCES A $3.7 MILLION PRIVATE PLACEMENT

Transaction Led Primarily by Existing Investors to Accelerate LightSolver's Laser-Based Supercomputing Development REHOVOT, Israel, Oct. 9, 2026 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), an innovative technology company operating at the intersection of deep-tech photonic computing and biotechnology  today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 989,301 of the Company's ordinary shares (or ordinary share equivalents in lieu thereof) and unregistered warrants to purchase up to 1,483,952 ordinary shares in a private placement at a combined purchase price of $3.74 per ordinary share and accompanying warrants (or $3.7399 per ordinary share equivalent and accompanying warrants). The private placement, which is comprised primarily of the Company's existing investors, reflects confidence in CollPlant's expanded strategic vision and its execution capabilities in deep-tech photonic computing.

PRNewsWire10/9/2026Neutral
LightSolver Files U.S. Provisional Patent Application Expanding its Photonic Computing Platform to Advanced Scientific and Engineering Simulations

CollPlant Advances its Photonic Computing Strategy Through LightSolver's Growing IP Portfolio REHOVOT, Israel, Oct. 6, 2026 /PRNewswire/ -- CollPlant Biotechnologies Ltd. (Nasdaq: CLGN) today announced that its subsidiary, LightSolver, has filed a provisional patent application with the U.S. Patent and Trademark Office (USPTO) for an invention that significantly expands the capabilities of its all-optical, laser-based computing platform.

PRNewsWire10/6/2026Neutral
COLLPLANT REPORTS 2026 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Strategic Expansion into Photonic Computing via LightSolver Acquisition Diversifies Technology Portfolio Alongside Continued Innovations in Regenerative Medicine REHOVOT, Israel, Sept. 30, 2026 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), today announced financial results for the second quarter of 2026 and provided a corporate update.

PRNewsWire9/30/2026Neutral
LightSolver, a CollPlant Company, and HLRS Joint Research Demonstrated Photonic Computing Can significantly Accelerate Fundamental HPC Workloads

Peer-reviewed study published by ACM: LightSolver's LPU architecture demonstrated significantly lower projected time-to-solution, compared to state-of-the-art algorithms running on a GPU REHOVOT, Israel, September 24, 2026 /PRNewswire/ -- CollPlant Biotechnologies Ltd. (Nasdaq: CLGN) today announced the publication of joint research conducted by its subsidiary LightSolver Ltd.

PRNewsWire9/24/2026Neutral
CollPlant Regains Compliance with Nasdaq Minimum Bid Price Requirement

Nasdaq confirms the Company satisfies continued listing criteria under Listing Rule 5550(a)(2), officially closing the compliance matter Follows the recent completion of the LightSolver acquisition, marking CollPlant's strategic expansion into high-performance computing (HPC) and photonics REHOVOT, Israel, Sept. 22, 2026 /PRNewswire/ -- CollPlant Biotechnologies Ltd.

PRNewsWire9/22/2026Neutral
COLLPLANT COMPLETES ACQUISITION OF LIGHTSOLVER, ENTERING THE PHOTONIC COMPUTING SECTOR

Technological Edge - LightSolver advances the development of the world's first Laser Processing Unit (LPU) – an energy-efficient, pure photonic computing platform Accelerated Growth Path - The transaction positions LightSolver to accelerate its path towards commercialization and expand engagements with strategic partners. REHOVOT, Israel, Sept.

PRNewsWire9/3/2026Neutral

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CLGN and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

Data last updated: 10/17/2026